Skip to main content
First-Line Ensartinib (X396) versus Crizotinib in Advanced ALK-Rearranged NSCLC (eXalt3): A Randomized, Open-Label, Phase 3 Study Wu, Y., Mok, T., Reck, M., Wakelee, H., Liang, C., Tan, F., Harrow, K., Oertel, V., Dukart, G., Ding, L., Horn, L. ELSEVIER SCIENCE INC. 2017: S2402

View details for DOI 10.1016/j.jtho.2017.11.025

View details for Web of Science ID 000463860802561